ImmunityBio Ranks Among Top 10 Most Shorted with 40.85% Short Interest
ImmunityBio's shares registered a 40.85% short interest rate on Feb. 13, ranking it among the top-10 most-shorted stocks with market caps above $2 billion. Elevated short interest heightens potential for a volatile short squeeze or accelerated declines, underscoring significant risk for current holders and opportunities for speculative traders.
1. Short Interest Overview
On Feb. 13, ImmunityBio recorded a 40.85% short interest, placing it within the top 10 most-shorted stocks with market capitalizations exceeding $2 billion. This level of short interest reflects substantial pessimism among institutional and retail investors about the company’s near-term prospects.
2. Investor Implications
Such elevated short interest can trigger pronounced volatility: a sharp price uptick could force short sellers to cover positions, driving a rapid short squeeze, while negative developments could amplify downward pressure. Investors should weigh the heightened risk and potential reward, conduct thorough due diligence, and monitor trading dynamics closely.